StreetInsider.com News Articles

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 16 Oct 2026 16:15:00 -0400

WALTHAM, Mass., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that on October 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted an aggregate of 74,900 restricted stock units of the Company’s common stock (“RSUs”) to newly hired employees of the Company as an inducement material to such employees’ entry into employment with the Company, in

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 16 Oct 2026 16:15:00 -0400

H.C. Wainwright Reiterates Buy Rating on Zenas Biopharma (ZBIO)

Tue, 13 Oct 2026 06:50:32 -0400

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating and $44.00 price target on Zenas Biopharma (NASDAQ: ZBIO).

The analyst commented: "Zenas BioPharma presented new data for bifunctional mAb CD19 and FcγRIIb inhibitor obexelimab in immunoglobulin G4-related disease (IgG4-RD), including longer-term findings from the Phase 3 INDIGO open-label extension (OLE), a glucocorticoid toxicity analysis, and initial vaccine response data. We believe the key takeaways center around: (1) additional evidence supporting reduced cumulative glucocorticoid toxicity; (2) sustained flare protection with continued obexelimab treatment; and (3) preliminary evidence of vaccine responsiveness following a treatment-free window. In the randomized, controlled period, obexelimab significantly reduced

Form 8-K Zenas BioPharma, Inc. For: Oct 12

Tue, 13 Oct 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20261013/27176294.html

Zenas BioPharma shares new obexelimab data for IgG4-RD treatment

Mon, 12 Oct 2026 07:01:36 -0400

Zenas BioPharma, Inc. (Nasdaq: ZBIO) presented new clinical data on obexelimab in immunoglobulin G4-related disease (IgG4-RD) at the 6th International Symposium on IgG4-Related Disease, held Oct. 8-10, 2026, in Cambridge, Massachusetts.

Data from the Phase 3 INDIGO open-label extension showed that patients receiving 250 mg obexelimab subcutaneously once weekly had a 12-month probability of remaining flare-free of 0.93, based on investigator- and adjudication committee-confirmed flares requiring rescue therapy. The median cumulative glucocorticoid rescue dose was 0 mg, with a mean of 105 mg. Adverse event rates were comparable to or lower than those observed during the randomized, controlled period.

A sub-analysis of

Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease

Mon, 12 Oct 2026 07:00:00 -0400

– Phase 3 INDIGO open-label extension findings demonstrated sustained clinical activity of obexelimab –

– Additional analyses of secondary endpoints showed that significantly fewer patients experienced clinically meaningful cumulative glucocorticoid toxicity at week 52 –

– Initial open-label extension sub-study findings demonstrated vaccine responses following a treatment-free window –

– These new findings add to the clinical evidence supporting obexelimab’s investigational role as a reversible, steroid-sparing, B-cell inhibitor for the treatment of IgG4-RD –

WALTHAM, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”)

Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease

Mon, 12 Oct 2026 07:00:00 -0400

– Phase 3 INDIGO open-label extension findings demonstrated sustained clinical activity of obexelimab –

– Additional analyses of secondary endpoints showed that significantly fewer patients experienced clinically meaningful cumulative glucocorticoid toxicity at week 52 –

– Initial open-label extension sub-study findings demonstrated vaccine responses following a treatment-free window –

– These new findings add to the clinical evidence supporting obexelimab’s investigational role as a reversible, steroid-sparing, B-cell inhibitor for the treatment of IgG4-RD –

WALTHAM, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”)

Zenas BioPharma to present MS drug data at MSToronto2026

Wed, 07 Oct 2026 07:05:52 -0400

Zenas BioPharma, Inc. (Nasdaq: ZBIO) announced it will present seven posters at the 10th Joint ACTRIMS-ECTRIMS Meeting, known as MSToronto2026, scheduled for October 21-23, 2026, in Toronto, Canada.

The presentations will cover data on orelabrutinib in relapsing-remitting multiple sclerosis (MS), trial designs for Phase 3 studies in progressive MS subtypes, and data on obexelimab in relapsing MS.

Poster topics include pharmacokinetics of orelabrutinib from a Phase 2 study in relapsing-remitting MS, the design of the Monarch Phase 3 trial of orelabrutinib in non-active secondary progressive MS, and the design of the PriMroSe Phase 3 trial in primary progressive MS. Three additional posters

Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis

Wed, 07 Oct 2026 07:05:00 -0400

WALTHAM, Mass., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company advancing therapies for patients living with autoimmune and inflammatory diseases, today announced that it will present seven posters at the 10^th Joint ACTRIMS-ECTRIMS Meeting (MSToronto2026) taking place October 21-23, 2026, in Toronto, Canada.

The Company will also host a Symposium featuring a panel of Multiple Sclerosis (MS) experts discussing the evolving science and clinical potential of BTK inhibition in progressive MS.

Symposium Details:

Title: BTK Inhibition in MS: An Emerging Approach to Disability

Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis

Wed, 07 Oct 2026 07:05:00 -0400

The Company will also host a Symposium featuring a panel of Multiple Sclerosis (MS) experts discussing the evolving science and clinical potential of BTK inhibition in progressive MS.

Symposium Details:

Title: BTK Inhibition in MS: An Emerging Approach to Disability

Zenas BioPharma to Host Virtual R&D Event

Tue, 06 Oct 2026 07:05:00 -0400

WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that it will host a virtual R&D event on Tuesday, October 27, 2026, from 8:00 – 9:30 a.m. ET.

The event will include presentations from Zenas’ management team on the overall R&D pipeline including obexelimab, our investigational bifunctional monoclonal antibody targeting CD19 and FcyRIIb, currently being evaluated in systemic lupus

Zenas BioPharma to Host Virtual R&D Event

Tue, 06 Oct 2026 07:05:00 -0400

Zenas BioPharma to Host Virtual R&D Event

Tue, 06 Oct 2026 07:05:00 -0400

Zenas BioPharma to Host Virtual R&D Event

Tue, 06 Oct 2026 07:05:00 -0400

Zenas Biopharma (ZBIO) PT Raised to $48 at Citi

Wed, 30 Sep 2026 10:01:11 -0400

Citi analyst Yigal Nochomovitz raised the price target on Zenas Biopharma (NASDAQ: ZBIO) to $48.00 (from $41.00) while maintaining a Buy rating.

H.C. Wainwright Reiterates Buy Rating on Zenas Biopharma (ZBIO)

Wed, 30 Sep 2026 07:17:45 -0400

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating and $44.00 price target on Zenas Biopharma (NASDAQ: ZBIO).

The analyst commented: "Zenas BioPharma hosted an IgG4-RD investor event focused on bifunctional mAb CD19 and FcγRIIb inhibitor obexelimab, for the treatment of immunoglobulin G4-related disease (IgG4-RD), which has a PDUFA target action date of May 27, 2027. We believe key points from the discussion centered around: (1) the KOL perspective on differentiation and anticipated first-line utilization of obexelimab in IgG4-RD; along with (2) discussion from the company on the commercial opportunity positioning as well as prelaunch preparedness strategies. We remind investors that

Guggenheim Reiterates Buy Rating on Zenas Biopharma (ZBIO)

Wed, 30 Sep 2026 05:57:38 -0400

Guggenheim analyst Yatin Suneja reiterated a Buy rating and $55.00 price target on Zenas Biopharma (NASDAQ: ZBIO)

The analyst comments "On today's Investor Day, ZBIO mgmt put in perspective the commercial opportunity for obexelimab (obexe; anti-CD19xFc¥ãRIIb bifunctional B cell-inhibiting antibody) in IgG4-RD. PDUFA date is May 27th, 2027, and the company expects to be launch ready. The KOL on the call appeared clearly positive and believes obexe is significantly differentiated from the currently approved CD20/19 depleters, with a real shot at front-line treatment. ZBIO is anchoring AMGN's Uplizna's IgG4-RD launch as the "proof-of-market": ~1.2K new patients treated, implying a $400-500MM run

Zenas BioPharma to present obexelimab IgG4-RD data at two meetings

Tue, 22 Sep 2026 07:05:45 -0400

Zenas BioPharma, Inc. (Nasdaq: ZBIO) announced it will present new data from its Phase 3 INDIGO trial evaluating obexelimab in immunoglobulin G4-related disease (IgG4-RD) at two scientific meetings this fall, according to a company press release.

The presentations will take place at the 6th International Symposium on IgG4-Related Disease, scheduled for October 8-10 in Cambridge, Massachusetts, and at ACR Convergence 2026, running November 6-11 in Orlando, Florida.

At the October symposium, two oral presentations are scheduled for October 10. One will cover longer-term efficacy and safety data from the INDIGO open-label extension, to be presented by Emma Culver of the University of

Zenas BioPharma to present obexelimab IgG4-RD data at two meetings

Tue, 22 Sep 2026 07:05:45 -0400

Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026

Tue, 22 Sep 2026 07:05:00 -0400

– New data from the Phase 3 INDIGO open-label extension will include the longer-term flare protection and safety data of obexelimab in IgG4-RD –

– Additional analyses will assess glucocorticoid-associated toxicity and vaccine responses –

WALTHAM, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company advancing therapies for patients living with autoimmune and inflammatory diseases, today announced that new data from the Phase 3 INDIGO trial evaluating obexelimab in immunoglobulin G4-related disease (IgG4-RD) will be presented at two upcoming scientific meetings:

Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026

Tue, 22 Sep 2026 07:05:00 -0400

– New data from the Phase 3 INDIGO open-label extension will include the longer-term flare protection and safety data of obexelimab in IgG4-RD –

– Additional analyses will assess glucocorticoid-associated toxicity and vaccine responses –

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 18 Sep 2026 16:15:00 -0400

WALTHAM, Mass., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that on September 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 53,700 shares of the Company’s common stock (“Stock Options”) and an aggregate of 98,900 restricted stock units of the Company’s common stock (“RSUs”) to newly hired

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 18 Sep 2026 16:15:00 -0400

Zenas BioPharma (ZBIO) files for up to 7M share offering by selling stockholders

Fri, 11 Sep 2026 16:52:36 -0400

Zenas BioPharma (NASDAQ: ZBIO) filed for up to 7,000,000 share offering by selling stockholders.

Zenas BioPharma (ZBIO) files for up to 7M share offering by selling stockholders

Fri, 11 Sep 2026 16:52:36 -0400

Zenas BioPharma (NASDAQ: ZBIO) filed for up to 7,000,000 share offering by selling stockholders.